

GENOMMA LAB INTERNACIONAL INFORMS CHANGES TO BOARD OF DIRECTORS AND COMMITTEES

Mexico City, April 30, 2019 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence, today informed that, as of yesterday, according to the Annual General Shareholders Meeting, the Board of Directors is now integrated by the following members: Rodrigo Alonso Herrera Aspra as Chairman, Jorge Ricardo Gutiérrez Muñoz, Juan Alonso, Javier Vale Castilla, Ignacio González Rodríguez, Burkhard Wittek, Carlos Javier Vara Alonso, Juan Carlos Gavito Aspe and Sabrina Lucila Herrera Aspra. All of them, except for Rodrigo Alonso Herrera Aspra, Sabrina Herrera Aspra and Burkhard Witeek, are independent members of the Board.

Additionally, the Company announces that it has received the resignation of: (i) Scott R. Emerson as independent Board member; and (ii) Héctor Carrillo González as independent Board member and member of the Audit and Corporate Practices Committee.

The Audit and Corporate Practices Committee is now integrated by the following members: Jorge Ricardo Gutiérrez Muñoz as President, Juan Alonso and Juan Carlos Gavito Aspe as members.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com

Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “**LABB**” (**Bloomberg: LABB-MM**).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Mexico:

Enrique González Casillas +5255 508100 inversion@genommalab.com

New York:

Bárbara Cano +1 (646) 452 23 34 barbara@inspigroup.com